PMID- 12403936
OWN - NLM
STAT- MEDLINE
DCOM- 20021210
LR  - 20171101
IS  - 1018-2438 (Print)
IS  - 1018-2438 (Linking)
VI  - 129
IP  - 2
DP  - 2002 Oct
TI  - Aberrant Fas ligand expression in lymphocytes in patients with Behcet's disease.
PG  - 175-80
AB  - BACKGROUND: Defects in immune responses have been reported in patients with 
      Behcet's disease (BD). To further characterize the immune dysfunction and its 
      contribution to the pathogenesis, we have studied Fas ligand (FasL) expression in 
      peripheral blood lymphocytes (PBL) and mononuclear cells in the skin lesions in 
      patients with BD. METHODS: FasL expression in PBL was studied with RT-PCR and 
      immunoblotting with rabbit anti-human FasL antibody. We studied the expression of 
      FasL in cryostat sections of biopsy specimens of erythema nodosum lesions from 4 
      patients with BD and of a genital ulcer lesion in another patient using 
      immunohistochemical staining. Apoptotic cell death was detected with the terminal 
      deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) method. 
      RESULTS: We found that FasL mRNA and FasL protein expression was detected 
      marginally in the unstimulated PBL, and was induced upon activation in normal 
      individuals. PBL from patients with BD exhibited an enhanced expression of FasL 
      mRNA and FasL protein without in vitro stimulation. Moreover, mitogen stimulation 
      failed to augment FasL expression of their lymphocytes, suggesting a 
      dysregulation of FasL expression of PBL in patients with BD. The skin biopsy 
      specimens revealed that cells infiltrating into skin lesions expressed FasL and 
      there were several TUNEL staining-positive cells in the lesions, suggesting that 
      Fas/FasL-mediated apoptosis is involved in the development of the skin lesion and 
      thus may be associated with the pathogenesis. CONCLUSIONS: We found an excessive 
      expression of FasL in circulating as well as skin-infiltrating lymphocytes and 
      the presence of apoptotic cells in the skin lesions, suggesting that lymphocytes 
      expressing FasL aberrantly may play a role in the development and pathogenesis of 
      BD.
CI  - Copyright 2002 S. Karger AG, Basel
FAU - Wakisaka, Sueshige
AU  - Wakisaka S
AD  - Department of Immunology, St. Marianna University School of Medicine, Kawasaki, 
      Kanagawa, Japan.
FAU - Takeba, Yuko
AU  - Takeba Y
FAU - Mihara, Shoji
AU  - Mihara S
FAU - Takeno, Mhoso
AU  - Takeno M
FAU - Yamamoto, Shoso
AU  - Yamamoto S
FAU - Sakane, Tsuyoshi
AU  - Sakane T
FAU - Suzuki, Noboru
AU  - Suzuki N
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Int Arch Allergy Immunol
JT  - International archives of allergy and immunology
JID - 9211652
RN  - 0 (FASLG protein, human)
RN  - 0 (Fas Ligand Protein)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Adult
MH  - Apoptosis/immunology
MH  - Behcet Syndrome/blood/*immunology/metabolism/pathology
MH  - Fas Ligand Protein
MH  - Humans
MH  - Immunoblotting
MH  - In Situ Nick-End Labeling
MH  - Lymphocytes/immunology/*metabolism
MH  - Membrane Glycoproteins/*biosynthesis/blood/genetics/immunology
MH  - Middle Aged
MH  - RNA, Messenger/biosynthesis/genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
EDAT- 2002/10/31 04:00
MHDA- 2002/12/11 04:00
CRDT- 2002/10/31 04:00
PHST- 2002/10/31 04:00 [pubmed]
PHST- 2002/12/11 04:00 [medline]
PHST- 2002/10/31 04:00 [entrez]
AID - 65878 [pii]
AID - 10.1159/000065878 [doi]
PST - ppublish
SO  - Int Arch Allergy Immunol. 2002 Oct;129(2):175-80. doi: 10.1159/000065878.